AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oligonucleotide-based therapies for functional cure of chronic hepatitis B (CHB), today announced full end-of-follow-up (EOF) data from its Phase IIa study (AB-10-8002) of AHB-137, the company’s lead investigational HBV therapeutic product.
